Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00449865 · ClinicalTrials.gov registry record · Phase 3
NET-PD LS-1 Creatine in Parkinson's Disease
A Phase 3 study, sponsored by University of Rochester.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,741
- Enrollment target
NCT00449865: Clinical Trial Phase 3 study, sponsored by University of Rochester.
NCT00449865 is a Phase 3 study that was terminated before completion, run by University of Rochester. The registered enrollment target is 1,741 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (126% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00449865, a Phase 3 study, was terminated before completion, sponsored by University of Rochester.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,741 participants
- Enrollment target
Study Summary
The purpose of this trial is to determine if the nutritional supplement creatine slows the progression of Parkinson's disease over time.
Primary Outcome
All outcomes were coded such that higher scores indicated worse outcomes. Patients were ranked on each outcome and their ranks were summed (summed-ranks). Higher summed ranks (range, 5-4775) indicate worse outcomes. The mean summed ranks were compared by treatment group by a global statistical test (GST).
Interventions
- OTHER placebo
- DRUG creatine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,741 participants |
| Start Date | 2007-03 |
| Est. Completion | 2014-05 |
| Phase | Phase 3 |
Why NCT00449865 stopped before completion
NCT00449865 is an interventional study that assigns participants to a tested intervention. Its 1,741 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (126% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00449865 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00449865 about?
NCT00449865 is a clinical study titled "NET-PD LS-1 Creatine in Parkinson's Disease". The purpose of this trial is to determine if the nutritional supplement creatine slows the progression of Parkinson's disease over time.
What is the current status of trial NCT00449865?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,741 participants. The study started on 2007-03. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00449865?
The interventions under investigation include: placebo (OTHER), creatine (DRUG).
Who is sponsoring clinical trial NCT00449865?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00449865's enrollment target sits among peer trials
1,741 129th of 2000 higher than 1,872 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04712656 · 1,739 participants
Effects of CPAP Therapy on Blood Pressure and Heart Rate Variability in Obstructive Sleep Apnea
- NCT05934487 · 1,750 participants · NA
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
- NCT06954337 · 1,750 participants · NA
MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial
- NCT07183527 · 1,750 participants · NA
Hybrid Type I Effectiveness-implementation Cluster Randomized Controlled Trial of CARES
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia